Comparison of the efficacy and impact on cognition of glycopyrrolate and biperiden for clozapine-induced sialorrhea in schizophrenic patients: A randomized, double-blind, crossover study

Schizophrenia Research

Volumn 119, Issue 1-3, 2010, Pages 138-144

  Liang, Chih Sung ^a   Ho, Pei Shen ^a   Shen, Lih Jong ^b   Lee, Wen Kuei ^a   Yang, Fei Wen ^a   Chiang, Kuo Tung ^a  

^a Beitou Armed Forces Hospital   (Taiwan)

^b TAOYUAN ARMED FORCES GENERAL HOSPITAL   (Taiwan)

Author keywords

Biperiden; Clozapine; Cognition; Glycopyrrolate; Schizophrenia; Sialorrhea

Indexed keywords

BIPERIDEN; CLOZAPINE; GLYCOPYRRONIUM BROMIDE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE CONTROL; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HYPERSALIVATION; MALE; MINI MENTAL STATE EXAMINATION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCHIZOPHRENIA; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; ANTIPSYCHOTIC AGENTS; BIPERIDEN; CLOZAPINE; COGNITION; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; GLYCOPYRROLATE; HUMANS; MALE; MENTAL STATUS SCHEDULE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; SCHIZOPHRENIA; SIALORRHEA; TAIWAN;

EID: 77952672152     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2010.02.1060     Document Type: Article

References (55)

1. Abboud T.K., Read J., Miller F., Chen T., Valle R., Henriksen E.H. Use of glycopyrrolate in the parturient: effect on the maternal and fetal heart and uterine activity. Obstet. Gynecol. 1981, 57(2):224-227.
2. Adamus W.S., Leonard J.P., Troger W. Phase I clinical trials with WAL 2014, a new muscarinic agonist for the treatment of Alzheimer's disease. Life Sci. 1995, 56(11-12):883-890.
3. Atri A., Sherman S., Norman K.A., Kirchhoff B.A., Nicolas M.M., Greicius M.D., Cramer S.C., Breiter H.C., Hasselmo M.E., Stern C.E. Blockade of central cholinergic receptors impairs new learning and increases proactive interference in a word paired-associate memory task. Behav. Neurosci. 2004, 118(1):223-236.
4. Bai Y.M., Lin C.C., Chen J.Y., Liu W.C. Therapeutic effect of pirenzepine for clozapine-induced hypersalivation: a randomized, double-blind, placebo-controlled, cross-over study. J. Clin. Psychopharmacol. 2001, 21(6):608-611.
5. Baldessarini R.J., Frankenburg F.R. Clozapine. A novel antipsychotic agent. N. Engl. J. Med. 1991, 324(11):746-754.
6. Bartels S.J., Mueser K.T., Miles K.M. A comparative study of elderly patients with schizophrenia and bipolar disorder in nursing homes and the community. Schizophr. Res. 1997, 27(2-3):181-190.
7. Baum B.J. Principles of saliva secretion. Ann. N. Y. Acad. Sci. 1993, 694:17-23.
8. Berlan M., Montastruc J.L., Lafontan M. Pharmacological prospects for alpha 2-adrenoceptor antagonist therapy. Trends Pharmacol. Sci. 1992, 13(7):277-282.
9. Blasco P.A., Stansbury J.C. Glycopyrrolate treatment of chronic drooling. Arch. Pediatr. Adolesc. Med. 1996, 150(9):932-935.
10. Bonner T.I. New subtypes of muscarinic acetylcholine receptors. Trends Pharmacol. Sci. 1989, 11-15. (Suppl.).
11. Brebion G., Bressan R.A., Amador X., Malaspina D., Gorman J.M. Medications and verbal memory impairment in schizophrenia: the role of anticholinergic drugs. Psychol. Med. 2004, 34(2):369-374.
12. Brown D.V., Heller F., Barkin R. Anticholinergic syndrome after anesthesia: a case report and review. Am. J. Ther. 2004, 11(2):144-153.
13. Carlson G.W. The salivary glands. Embryology, anatomy, and surgical applications. Surg. Clin. North Am. 2000, 80(1):261-273. xii.
14. Dickerson F., Boronow J.J., Ringel N., Parente F. Neurocognitive deficits and social functioning in outpatients with schizophrenia. Schizophr. Res. 1996, 21(2):75-83.
15. Dorje F., Levey A.I., Brann M.R. Immunological detection of muscarinic receptor subtype proteins (m1-m5) in rabbit peripheral tissues. Mol. Pharmacol. 1991, 40(4):459-462.
16. Drimer T., Shahal B., Barak Y. Effects of discontinuation of long-term anticholinergic treatment in elderly schizophrenia patients. Int. Clin. Psychopharmacol. 2004, 19(1):27-29.
17. Duggal H.S. Glycopyrrolate for clozapine-induced sialorrhea. Prog. Neuropsychopharmacol. Biol. Psychiatry 2007, 31(7):1546-1547.
18. Eltze M., Figala V. Affinity and selectivity of biperiden enantiomers for muscarinic receptor subtypes. Eur. J. Pharmacol. 1988, 158(1-2):11-19.
19. Folstein M.F., Folstein S.E., McHugh P.R. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 1975, 12(3):189-198.
20. Fritze J., Elliger T. Pirenzepine for clozapine-induced hypersalivation. Lancet 1995, 346(8981):1034.
21. Fuder H., Meincke M. Glycopyrronium bromide blocks differentially responses mediated by muscarinic receptor subtypes. Naunyn Schmiedebergs Arch. Pharmacol. 1993, 347(6):591-595.
22. Gautam D., Heard T.S., Cui Y., Miller G., Bloodworth L., Wess J. Cholinergic stimulation of salivary secretion studied with M1 and M3 muscarinic receptor single- and double-knockout mice. Mol. Pharmacol. 2004, 66(2):260-267.
23. Green M.F. What are the functional consequences of neurocognitive deficits in schizophrenia?. Am. J. Psychiatry 1996, 153(3):321-330.
24. Grohmann R., Ruther E., Sassim N., Schmidt L.G. Adverse effects of clozapine. Psychopharmacology (Berl) 1989, 99(Suppl. 1):S101-S104.
25. Haddad E.B., Patel H., Keeling J.E., Yacoub M.H., Barnes P.J., Belvisi M.G. Pharmacological characterization of the muscarinic receptor antagonist, glycopyrrolate, in human and guinea-pig airways. Br. J. Pharmacol. 1999, 127(2):413-420.
26. Heinik J. Effects of trihexyphenidyl on MMSE and CAMCOG scores of medicated elderly patients with schizophrenia. Int. Psychogeriatr. 1998, 10(1):103-108.
27. Iqbal M.M., Rahman A., Husain Z., Mahmud S.Z., Ryan W.G., Feldman J.M. Clozapine: a clinical review of adverse effects and management. Ann. Clin. Psychiatry 2003, 15(1):33-48.
28. Kongsrud F., Sponheim S. A comparison of atropine and glycopyrrolate in anaesthetic practice. Acta Anaesthesiol. Scand. 1982, 26(6):620-625.
29. Lewis S.W., Barnes T.R., Davies L., Murray R.M., Dunn G., Hayhurst K.P., Markwick A., Lloyd H., Jones P.B. Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophr. Bull. 2006, 32(4):715-723.
30. Lingjaerde O., Ahlfors U.G., Bech P., Dencker S.J., Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr. Scand. Suppl. 1987, 334:1-100.
31. McEvoy J.P., Freter S. The dose-response relationship for memory impairment by anticholinergic drugs. Compr. Psychiatry 1989, 30(2):135-138.
32. McEvoy J.P., Lieberman J.A., Stroup T.S., Davis S.M., Meltzer H.Y., Rosenheck R.A., Swartz M.S., Perkins D.O., Keefe R.S., Davis C.E., Severe J., Hsiao J.K. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am. J. Psychiatry 2006, 163(4):600-610.
33. Michal P., Lysikova M., El-Fakahany E.E., Tucek S. Clozapine interaction with the M2 and M4 subtypes of muscarinic receptors. Eur. J. Pharmacol. 1999, 376(1-2):119-125.
34. Mier R.J., Bachrach S.J., Lakin R.C., Barker T., Childs J., Moran M. Treatment of sialorrhea with glycopyrrolate: a double-blind, dose-ranging study. Arch. Pediatr. Adolesc. Med. 2000, 154(12):1214-1218.
35. Mirakhur R.K., Dundee J.W. Glycopyrrolate: pharmacology and clinical use. Anaesthesia 1983, 38(12):1195-1204.
36. Mirakhur R.K., Dundee J.W., Jones C.J. Evaluation of the anticholinergic actions of glycopyrronium bromide. Br. J. Clin. Pharmacol. 1978, 5(1):77-84.
37. Moos D.D. Central anticholinergic syndrome: a case report. J. Perianesth. Nurs. 2007, 22(5):309-321.
38. Moritz S., Krausz M., Gottwalz E., Lambert M., Perro C., Ganzer S., Naber D. Cognitive dysfunction at baseline predicts symptomatic 1-year outcome in first-episode schizophrenics. Psychopathology 2000, 33(1):48-51.
39. Nakamura T., Matsui M., Uchida K., Futatsugi A., Kusakawa S., Matsumoto N., Nakamura K., Manabe T., Taketo M.M., Mikoshiba K. M(3) muscarinic acetylcholine receptor plays a critical role in parasympathetic control of salivation in mice. J. Physiol. 2004, 558(Pt 2):561-575.
40. Obisesan T.O., Obisesan O.A., Martins S., Alamgir L., Bond V., Maxwell C., Gillum R.F. High blood pressure, hypertension, and high pulse pressure are associated with poorer cognitive function in persons aged 60 and older: the Third National Health and Nutrition Examination Survey. J. Am. Geriatr. Soc. 2008, 56(3):501-509.
41. Olianas M.C., Maullu C., Onali P. Mixed agonist-antagonist properties of clozapine at different human cloned muscarinic receptor subtypes expressed in Chinese hamster ovary cells. Neuropsychopharmacology 1999, 20(3):263-270.
42. Praharaj S.K., Arora M., Gandotra S. Clozapine-induced sialorrhea: pathophysiology and management strategies. Psychopharmacology (Berl) 2006, 185(3):265-273.
43. Proakis A.G., Harris G.B. Comparative penetration of glycopyrrolate and atropine across the blood-brain and placental barriers in anesthetized dogs. Anesthesiology 1978, 48(5):339-344.
44. Proctor G.B., Carpenter G.H. Regulation of salivary gland function by autonomic nerves. Auton. Neurosci. 2007, 133(1):3-18.
45. Regine W.F., Scott C., Murray K., Curran W. Neurocognitive outcome in brain metastases patients treated with accelerated-fractionation vs. accelerated-hyperfractionated radiotherapy: an analysis from Radiation Therapy Oncology Group Study 91-04. Int. J. Radiat. Oncol. Biol. Phys. 2001, 51(3):711-717.
46. Richardson C., Kelly D.L., Conley R.R. Biperiden for excessive sweating from clozapine. Am. J. Psychiatry 2001, 158(8):1329-1330.
47. Robb A.S., Lee R.H., Cooper E.B., Siedel J.V., Nusrat N. Glycopyrrolate for treatment of clozapine-induced sialorrhea in three adolescents. J. Child Adolesc. Psychopharmacol. 2008, 18(1):99-107.
48. Schneider B., Weigmann H., Hiemke C., Weber B., Fritze J. Reduction of clozapine-induced hypersalivation by pirenzepine is safe. Pharmacopsychiatry 2004, 37(2):43-45.
49. Scully C. Drug effects on salivary glands: dry mouth. Oral Dis. 2003, 9(4):165-176.
50. Silver H., Geraisy N. Effects of biperiden and amantadine on memory in medicated chronic schizophrenic patients. A double-blind cross-over study. Br. J. Psychiatry 1995, 166(2):241-243.
51. Spohn H.E., Strauss M.E. Relation of neuroleptic and anticholinergic medication to cognitive functions in schizophrenia. J. Abnorm. Psychol. 1989, 98(4):367-380.
52. Strauss M.E., Reynolds K.S., Jayaram G., Tune L.E. Effects of anticholinergic medication on memory in schizophrenia. Schizophr. Res. 1990, 3(2):127-129.
53. Thomas-Stonell N., Greenberg J. Three treatment approaches and clinical factors in the reduction of drooling. Dysphagia 1988, 3(2):73-78.
54. Wagstaff A.J., Bryson H.M. Clozapine: a review of its pharmacological properties and therapeutic use in patients with schizophrenia who are unresponsive to or intolerant of classical antipsychotic agents. CNS Drugs 1995, 4(5):370-400.
55. Yusufi B., Mukherjee S., Flanagan R., Paton C., Dunn G., Page E., Barnes T.R. Prevalence and nature of side effects during clozapine maintenance treatment and the relationship with clozapine dose and plasma concentration. Int. Clin. Psychopharmacol. 2007, 22(4):238-243.